Citigroup analyst John Deakin-Bell upgrades ResMed (NYSE:RMD) from Neutral to Buy.
Analyst Trims Superior Group Of Companies’ Price Target By 10% Amidst Macro Uncertainty
Barrington Research analyst Kevin Steinke reiterated an Outperform rating on the shares of Superior Group of Companies Inc (NASDAQ:SGC) and lowered the…